Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

ABSTRACT:

Background

Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions.

Methods

We enrolled patients with consecutively and prospectively identified TRK fusion-positive cancers, detected by molecular profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1-2 study involving children, or a phase 2 study involving adolescents and adults. The primary end point for the combined analysis was the overall response rate according to independent review. Secondary end points included duration of response, progression-free sur

SUBMITTER: Drilon A 

PROVIDER: S-EPMC5857389 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature